Australia markets closed

10x Genomics, Inc. (TXG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.15+0.16 (+0.94%)
As of 12:58PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.03B
Enterprise value 1.75B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.21
Price/book (mrq)2.83
Enterprise value/revenue 2.80
Enterprise value/EBITDA -40.69

Trading information

Stock price history

Beta (5Y monthly) 1.84
52-week change 3-70.76%
S&P500 52-week change 323.95%
52-week high 363.57
52-week low 315.28
50-day moving average 322.34
200-day moving average 337.11

Share statistics

Avg vol (3-month) 31.82M
Avg vol (10-day) 32.63M
Shares outstanding 5105.65M
Implied shares outstanding 6119.71M
Float 8103.64M
% held by insiders 12.17%
% held by institutions 192.05%
Shares short (28 June 2024) 410.68M
Short ratio (28 June 2024) 47.9
Short % of float (28 June 2024) 411.72%
Short % of shares outstanding (28 June 2024) 48.92%
Shares short (prior month 31 May 2024) 49.92M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -42.26%
Operating margin (ttm)-42.12%

Management effectiveness

Return on assets (ttm)-13.06%
Return on equity (ttm)-34.75%

Income statement

Revenue (ttm)625.45M
Revenue per share (ttm)5.30
Quarterly revenue growth (yoy)5.00%
Gross profit (ttm)N/A
EBITDA -164.14M
Net income avi to common (ttm)-264.3M
Diluted EPS (ttm)-2.24
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)371.81M
Total cash per share (mrq)3.11
Total debt (mrq)92.18M
Total debt/equity (mrq)12.82%
Current ratio (mrq)5.22
Book value per share (mrq)6.01

Cash flow statement

Operating cash flow (ttm)-26.8M
Levered free cash flow (ttm)16.96M